Clementia Phase 2 Clinical Trial Site in London Now Enrolling Children aged 6-14

Tuesday, 10 November, 2015 - 09:45

Clementia is pleased to announce that its clinical trial site at The Royal National Orthopaedic Hospital in London, England is now ready to enroll children age 6 to 14 who meet the study eligibility criteria. This site joins the University of California San Francisco (UCSF) and the Necker Institute, Paris sites, which recently began enrolling children in Clementia’s Phase 2 study of Palovarotene for the treatment of fibrodysplasia ossificans progressiva (FOP).

As announced on September 28, 2015, enrollment of adults (age 15 years and older) is complete. Clementia are one step closer to completing enrollment in this study, thanks to the dedication of study participants, their families and the clinical site personnel. More information can be found about this trial at, enter NCT02190747 in the search bar.

All Content (C) Copyright FOP Friends 2018

FOP Friends is a Registered Charity in England and Wales #1147704

Website design by foliozine built by ONOS Ltd